Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.

abstract：:(E)-2'-deoxy-2'-(fluoromethylene) cytidine (MDL101,731) is a new deoxycytidine analog which shows potent antitumor activity against several human tumor models. We previously showed that MDL101,731 inhibited human ribonucleotide reductase (RNR) in HeLa S3 human cervical carcinoma cells. Recently, it has been reported t...

journal_title：Anti-cancer drugs

authors： Kanazawa J,Takahashi T,Akinaga S,Tamaoki T,Okabe M

更新日期：1998-08-01 00:00:00

abstract：:Since the number of patients seen in a pediatric oncology center is relatively small, it is difficult to perform single drug phase two studies, even on a national base. This also probably explains the lack of information on ifosfamide, despite the fact that it has now been used for more than 10 years in pediatrics. As...

journal_title：Anti-cancer drugs

authors： de Kraker J

更新日期：1991-08-01 00:00:00

abstract：:The aim of this study was to identify the most potent quinoline-based anti-infectives for the treatment of multiple myeloma (MM) and to understand the molecular mechanisms. A small-scale screen against a panel of marketed quinoline-based drugs was performed in MM cell lines. Cell apoptosis was examined by flow cytomet...

journal_title：Anti-cancer drugs

authors： Mao H,Du Y,Zhang Z,Cao B,Zhao J,Zhou H,Mao X

更新日期：2017-04-01 00:00:00

abstract：:This study aimed to further the understanding of the incidence of adverse events (AEs) in a population-based representative liver cancer population where there is currently a lack of knowledge. We carried out a retrospective cohort study using data from an administrative claims database between 1 January 2004 and 31 D...

journal_title：Anti-cancer drugs

authors： Dreyfus B,Kawabata HM,Gomez-Caminero A

更新日期：2013-07-01 00:00:00

abstract：:BPR0C305 is a novel N-substituted indolyl glyoxylamide previously reported with in-vitro cytotoxic activity against a panel of human cancer cells including P-gp-expressing multiple drug-resistant cell sublines. The present study further examined the underlying molecular mechanism of anticancer action and evaluated the...

journal_title：Anti-cancer drugs

authors： Li WT,Yeh TK,Song JS,Yang YN,Chen TW,Lin CH,Chen CP,Shen CC,Hsieh CC,Lin HL,Chao YS,Chen CT

更新日期：2013-11-01 00:00:00

abstract：:Organotypic cultures of human A549 cells were used as a tumor model to investigate sequence effects for combination treatments with adriamycin (ADR) and X-irradiation. Initial drug exposure led to the greatest cytotoxic effect especially when X-rays were delivered 24 h later and this subsequent irradiation did not sig...

journal_title：Anti-cancer drugs

authors： Chevillard S,Vielh P,Campana F,Bastian G,Coppey J

更新日期：1992-04-01 00:00:00

abstract：:Suramin is a polysulfonated naphthylurea currently investigated for the treatment of advanced malignancy. We have previously reported that suramin was a potent inducer of the differentiation of the human colic adenocarcinoma cell clone HT29-D4 (Fantini et al., J Biol Chem, 1989; 264: 10282-10286). In this report, we s...

journal_title：Anti-cancer drugs

authors： Baghdiguian S,Nickel P,Marvaldi J,Fantini J

更新日期：1990-10-01 00:00:00

abstract：:Macroautophagy (hereafter referred to as autophagy) plays essential roles in cellular and organismal homeostasis. Transcription factor EB (TFEB) is a master regulator of autophagy and lysosome biogenesis. It is not fully understood how the function of TFEB in autophagy pathway is regulated. Here, we show that Rac1 GTP...

journal_title：Anti-cancer drugs

authors： Ma L,Ma Y,Zhang Z,Wang Q,Liu X

更新日期：2019-11-01 00:00:00

abstract：:The co-operative effects of recombinant human tumor necrosis factor (rH-TNF) and CPT-11, a new derivative of camptothecin, against the proliferation of human gynecologic tumor cell lines were examined in vitro. The ishikawa cells were responsive to rH-TNF, the HHUA cells exhibited a minimal degree of responsiveness to...

journal_title：Anti-cancer drugs

authors： Mori H,Sawairi M,Itoh N,Hanabayashi T,Kondoh H,Tamaya T

更新日期：1991-10-01 00:00:00

abstract：:To compare the mechanical and chemical properties of three commercially available microspheres loaded with irinotecan. LifePearl (200 µm), DC Bead (100-300 µm), and Tandem (100 µm) microspheres were loaded with irinotecan. For loading, elution, and stability determinations, irinotecan concentrations were quantified us...

journal_title：Anti-cancer drugs

authors： Pereira PL,Plotkin S,Yu R,Sutter A,Wu Y,Sommer CM,Cruise GM

更新日期：2016-10-01 00:00:00

abstract：:The prognosis of children with high-grade glioma or high-risk neuroblastoma remains poor. Cilengitide is a selective antagonist of αvβ3 and αvβ5 integrins, which are involved in tumor growth and development of metastasis. We have evaluated the effects of cilengitide on pediatric glioma and neuroblastoma cell lines for...

journal_title：Anti-cancer drugs

authors： Leblond P,Dewitte A,Le Tinier F,Bal-Mahieu C,Baroncini M,Sarrazin T,Lartigau E,Lansiaux A,Meignan S

更新日期：2013-09-01 00:00:00

abstract：:The antitumor effect and tumor levels of 5-fluoro-2'-deoxyuridylate (FdUMP) following oral administration of tetradecyl 2'-deoxy-5-fluoro-5'-uridylate (TT-62) were compared with those attained following intravenous (i.v.) or intraperitoneal (i.p.) administration of 5-fluorouracil (5-FU) or 5-fluoro-2'-deoxyuridine (FU...

journal_title：Anti-cancer drugs

authors： Nakajima Y,Iigo M,Hoshi A

更新日期：1992-06-01 00:00:00

abstract：:Single-agent docetaxel induces a response in 21-42% of patients with recurrent squamous cell cancer of the head and neck (SCCHN). When used in combination with 5-fluorouracil (5-FU), response rates (RRs) of between 24 and 27% have been reported. In contrast, in combination with cisplatin, docetaxel has achieved a RR o...

journal_title：Anti-cancer drugs

authors： Posner MR

更新日期：2001-02-01 00:00:00

abstract：:The cytotoxic effects of Tomudex (TX) were investigated on a panel of 15 human tumor cell lines expressing a spontaneous sensitivity to the tested agent. We determined the basal cellular amount of relevant cellular factors potentially related to the cytotoxic efficacy of or resistance to TX. We selected thymidylate sy...

journal_title：Anti-cancer drugs

authors： Chéradame S,Chazal M,Fischel JL,Formento P,Renée N,Milano G

更新日期：1999-06-01 00:00:00

abstract：:Neuroblastoma is one of the most common cancers in infancy, arising from the neuroblasts during embryonic development. This cancer is difficult to treat and resistance to chemotherapy is often found; therefore, clinical trials of novel therapeutic approaches, such as targeted-cancer signaling, could be an alternative ...

journal_title：Anti-cancer drugs

authors： Suebsoonthron J,Jaroonwitchawan T,Yamabhai M,Noisa P

更新日期：2017-06-01 00:00:00

abstract：:Cancer stem cells play a fundamental role in the growth, metastasis, recurrence, and chemoresistance of cancers of various origins; therefore, targeting these cells may prospectively help to eradicate cancer cells from patients. In this study, the effect of tetrandrine on the proliferation of CD133-positive (CD133) He...

journal_title：Anti-cancer drugs

authors： Cui X,Xiao D,Wang X

更新日期：2019-10-01 00:00:00

abstract：:Dihydroartemisinin (DHA), a semisynthetic derivative of artemisinin, has recently shown antitumor activity in various cancer cells. Its effect on pancreatic cancer is, however, unknown and the mechanism is unclear. The study aims to investigate its antitumor activity and underlying mechanisms in human pancreatic cance...

journal_title：Anti-cancer drugs

authors： Chen H,Sun B,Pan S,Jiang H,Sun X

更新日期：2009-02-01 00:00:00

abstract：:Apalutamide (ARN-509) is an antiandrogen that binds selectively to androgen receptors (AR) and does not show antagonist-to-agonist switch like bicalutamide. We compared the activity of ARN versus bicalutamide on prostate cancer cell lines. The 22Rv1, PC3, and DU145 cell lines were used to study the effect of ARN and b...

journal_title：Anti-cancer drugs

authors： Koukourakis MI,Kakouratos C,Kalamida D,Mitrakas A,Pouliliou S,Xanthopoulou E,Papadopoulou E,Fasoulaki V,Giatromanolaki A

更新日期：2018-04-01 00:00:00

abstract：:Desmoid tumour/aggressive fibromatosis (DT/AF) is a rare soft-tissue neoplasm that is locally aggressive but does not metastasize. There is no standard systemic treatment for symptomatic patients, although a number of agents are used. Tyrosine kinase inhibitors have recently been reported to show useful activity. We r...

journal_title：Anti-cancer drugs

authors： Szucs Z,Messiou C,Wong HH,Hatcher H,Miah A,Zaidi S,van der Graaf WT,Judson I,Jones RL,Benson C

更新日期：2017-04-01 00:00:00

abstract：:Uterine sarcomas are rare tumors constituting 1-3% of all uterine malignancies. These tumors are characterized by aggressive growth and by poor overall prognosis. There is much controversy concerning diagnostic criteria and the great variation in histology, as well as the role of radiotherapy and chemotherapy in the m...

journal_title：Anti-cancer drugs

authors： Meden H,Meyer-Rath D,Schauer A,Kuhn W

更新日期：1991-02-01 00:00:00

abstract：:9-Nitrocamptothecin (9NC) is a water-insoluble topoisomerase I inhibitor with a broad antitumor activity in animal models. To determine the maximum tolerated oral dose (MTD), a phase I study was performed in patients with advanced cancer refractory to conventional chemotherapy. 9NC was administered orally with escalat...

journal_title：Anti-cancer drugs

authors： Verschraegen CF,Natelson EA,Giovanella BC,Kavanagh JJ,Kudelka AP,Freedman RS,Edwards CL,Ende K,Stehlin JS

更新日期：1998-01-01 00:00:00

abstract：:The mechanism of action of a synthetic compound--2,2'-bipyridyl-6-carbothioamide--was investigated by developing tumor lines resistant to it (P388-R1.5 and P388-R4). P388-R4 is resistant to inhibitors of ribonucleotide reductase (RR) while no resistance was observed to antitumor drugs having other targets (except to b...

journal_title：Anti-cancer drugs

authors： Nocentini G,Federici F,Armellini R,Franchetti P,Barzi A

更新日期：1990-12-01 00:00:00

abstract：:Our previous studies have shown that arsenic trioxide (As2O3), a novel anti-cancer agent, may be active against urothelial carcinomas. A series of bladder urothelial carcinoma cells with progressive As2O3 resistance were established and studied to reveal molecular events in relation to the mechanisms of resistance to ...

journal_title：Anti-cancer drugs

authors： Hour TC,Huang CY,Lin CC,Chen J,Guan JY,Lee JM,Pu YS

更新日期：2004-09-01 00:00:00

abstract：:Since 5-fluorouracil (5-FU) was synthesized in the late 1950s it has become an important component of many anticancer treatment regimens. The increasing volume of literature accumulating about this drug is evidence that the optimal administration schedule and its combination with modulators has yet to be determined. M...

journal_title：Anti-cancer drugs

authors： Findlay MP,Leach MO

更新日期：1994-06-01 00:00:00

abstract：:Hepatic and peritoneal metastases are the most frequent metastatic lesions in patients with gastrointestinal stromal tumors (GIST), and may result in intra- or extrahepatic cholestasis and altered drug metabolism. While the tyrosine kinase inhibitor imatinib, which has been recently shown to represent the treatment of...

journal_title：Anti-cancer drugs

authors： Bauer S,Hagen V,Pielken HJ,Bojko P,Seeber S,Schütte J

更新日期：2002-09-01 00:00:00

abstract：:The aims of this study were to investigate a clinical observation that patients with epithelial ovarian cancer treated with first-line platinum-paclitaxel chemotherapy combination (TP) develop macrocytosis and to explore the possible predictive role of macrocytosis in response rate, progression-free survival (PFS), an...

journal_title：Anti-cancer drugs

authors： Boraska Jelavić T,Boban T,Brčić L,Vrdoljak E

更新日期：2017-09-01 00:00:00

abstract：:Previous investigations have indicated the possibility to circumvent multidrug resistance (MDR) by incorporation of an anthracycline into liposomes. We examined the in vitro cytotoxicity and cellular drug accumulation of the anthracyclines daunorubicin and doxorubicin compared with the commercially available liposomal...

journal_title：Anti-cancer drugs

authors： Wang Y,Eksborg S,Lewensohn R,Lindberg A,Liliemark E

更新日期：1999-11-01 00:00:00

abstract：:A phase II study was performed to assess the safety and efficacy of mitoxantrone and cisplatin in locally recurrent and/or metastatic carcinomas of the salivary glands. Between May 1997 and March 2001, a total of 14 patients were entered on this trial. All of them had previously undergone radical resection and 10 were...

journal_title：Anti-cancer drugs

authors： Gedlicka C,Schüll B,Formanek M,Kornfehl J,Burian M,Knerer B,Selzer E,Scheithauer W,Kornek GV

更新日期：2002-06-01 00:00:00

abstract：:This study was performed to evaluate the role of protein kinase C (PKC) activity in the development of chemoresistance in clinical breast cancer cells. To simulate the clinical situation, native tumor cells derived from 10 patients with advanced breast cancer were brought into short-term cultures, and treated with ant...

journal_title：Anti-cancer drugs

authors： Schöndorf T,Hoopmann M,Breidenbach M,Rein DT,Göhring UJ,Becker M,Mallmann P,Kurbacher CM

更新日期：2004-03-01 00:00:00

abstract：:A new dosage format, cisplatin microcrystals suspended in oil (CDDP-oil), was developed for the treatment of peritoneal carcinomatoses. We studied the acute toxicity of CDDP-oil injected intraperitoneally in mice. The 50% lethal dose was 30.3 mg/kg (27.1-33.7 mg/kg at the 95% confidence level), which was 1.79 times th...

journal_title：Anti-cancer drugs

authors： Tsujimoto H,Hagiwara A,Sakakura C,Sasaki S,Osaki K,Ohyama T,Sakakibara T,Takahashi T

更新日期：1993-06-01 00:00:00